MLM
LSTA icon

Mount Lucas Management’s Lisata Therapeutics LSTA Stock Holding History

Mount Lucas Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-97
Closed -$16K – 136
2015
Q4 		$16K Buy
+97
New +$17.8K ﹤0.01% 108

Other funds holding LSTA

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Mount Lucas Management's LSTA Position: Q1 2016 in Review

Mount Lucas Management sold out of Lisata Therapeutics (LSTA) in Q1 2016, closing a stake of 97 shares — an estimated $16K sold.

Mount Lucas Management first reported a position in LSTA in Q4 2015 and held it in 1 quarter. The position peaked at $16K in Q4 2015. 44 funds tracked by Wall St. Rank hold LSTA as of Q1 2016.

  • Mount Lucas Management reported no remaining Lisata Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Mount Lucas Management sold 97 Lisata Therapeutics shares in Q1 2016, an estimated $16K.
  • Mount Lucas Management first reported a position in Lisata Therapeutics in Q4 2015 and held it in 1 quarter.
  • Mount Lucas Management's Lisata Therapeutics position peaked at $16K in Q4 2015.
  • 44 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2016.

Based on Mount Lucas Management's 13F filing for Q1 2016, filed 16 May 2016.